Alanyl-glutamine to help treat C. difficile diarrhea
Part of Digestive system, Infections clinical trials.
This study tests whether the supplement alanyl-glutamine, given along with standard treatment, can improve outcomes for adults being treated for C. difficile infection (a cause of diarrhea). It may help the body recover better after antibiotics that usually treat C. difficile.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can give consent (or have a legally authorized representative help).
- You have diarrhea and are being treated for a C. difficile infection.
- You started standard C. difficile treatment within the last 120 hours (oral vancomycin or fidaxomicin).
- You can take the study medicine by mouth or through a feeding tube.
- You can join the study at one of the participating hospitals/clinics and follow the study schedule.
- You do not have any major “not eligible” emergencies or complications listed by the study (like shock/ICU-level illness).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental treatment called CMTS0929 for people with a C. difficile infection that is causing diarrhea. The treatment is given through a tube placed through the nostril or mouth into the intestine, and the study will see if it is safe and helpful.
This trial compares three treatments for a severe diarrhea infection called C. diff: a fecal transplant (putting healthy donor stool into your gut), a newer antibiotic called fidaxomicin, and an older antibiotic called vancomycin. The goal is to see which works best and prevents the infection from coming back.
This study tests whether taking a capsule form of fecal microbiota transplant (FMT) can help adults with their first C. difficile infection—or a first relapse—get better and reduce repeat episodes. Participants also take specific antibiotics for C. difficile as part of the study process.
This study tests whether adding a common bile acid (ursodeoxycholic acid) to your regular C. diff treatment can help stop the infection from coming back. The goal is to see if this extra medicine reduces the chance of recurrence.
This study tests a new antibody (AZD5148) to prevent C. diff infection from coming back. If you have a current C. diff infection and are being treated with antibiotics, you may be able to join.
This trial tests whether giving vancomycin through a tube into the stomach can prevent a serious gut infection called C. diff in people who are very sick in the ICU and taking antibiotics. If you qualify, you might receive this medicine to lower your risk.
Hear when a new Clostridioides Difficile Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.